Stelios Tsigkos

972 total citations
19 papers, 757 citations indexed

About

Stelios Tsigkos is a scholar working on Molecular Biology, Economics and Econometrics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Stelios Tsigkos has authored 19 papers receiving a total of 757 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Economics and Econometrics and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Stelios Tsigkos's work include Health Systems, Economic Evaluations, Quality of Life (8 papers), Angiogenesis and VEGF in Cancer (6 papers) and Pharmaceutical Economics and Policy (4 papers). Stelios Tsigkos is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (8 papers), Angiogenesis and VEGF in Cancer (6 papers) and Pharmaceutical Economics and Policy (4 papers). Stelios Tsigkos collaborates with scholars based in Netherlands, Greece and Germany. Stelios Tsigkos's co-authors include Andreas Papapetropoulos, Αναστασία Κοτανίδου, Fiorentina Roviezzo, Vincenzo Brancaleone, Mariarosaria Bucci, Giuseppe Cirino, Charis Roussos, Spyros Zakynthinos, Constantinos Glynos and Christina Sotiropoulou and has published in prestigious journals such as Nature Reviews Drug Discovery, Journal of Allergy and Clinical Immunology and Critical Care Medicine.

In The Last Decade

Stelios Tsigkos

19 papers receiving 741 citations

Peers

Countries citing papers authored by Stelios Tsigkos

Since Specialization

Citations

This map shows the geographic impact of Stelios Tsigkos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stelios Tsigkos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stelios Tsigkos more than expected).

Fields of papers citing papers by Stelios Tsigkos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stelios Tsigkos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stelios Tsigkos. The network helps show where Stelios Tsigkos may publish in the future.

Co-authorship network of co-authors of Stelios Tsigkos

This figure shows the co-authorship network connecting the top 25 collaborators of Stelios Tsigkos. A scholar is included among the top collaborators of Stelios Tsigkos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stelios Tsigkos. Stelios Tsigkos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit–The EU Regulator's Perspective 2021 ·Frontiers in Medicine ·(unknown), (unknown), Giuseppe Capovilla, (unknown), (unknown), Segundo Mariz, Darius Matusevičius, Robert Nisticò, (unknown), Stelios Tsigkos, Kyriaki Tzogani, Kristina Larsson, Armando Magrelli, Violeta Stoyanova‐Beninska	3
2	Regulatory Standards in Orphan Medicinal Product Designation in the EU 2021 ·Frontiers in Medicine ·Stelios Tsigkos, Segundo Mariz, (unknown), Kristina Larsson, Armando Magrelli, Violeta Stoyanova‐Beninska	9
3	Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases 2019 ·Drug Discovery Today ·(unknown), (unknown), (unknown), Giuseppe Capovilla, Laura Fregonese, Matthias P. Hofer, Armando Magrelli, Segundo Mariz, (unknown), Robert Nisticò, (unknown), Nikolaos V. Sipsas, Stelios Tsigkos, Dinko Vitezić, Kristina Larsson, Bruno Sepodes, Violeta Stoyanova‐Beninska	4
4	Defining orphan conditions in the context of the European orphan regulation: challenges and evolution 2018 ·Nature Reviews Drug Discovery ·Daniel O’Connor, (unknown), Matthias P. Hofer, Stelios Tsigkos, Segundo Mariz, Laura Fregonese, Kristina Larsson, Virginie Hivert, Kerstin Westermark, (unknown), Violeta Stoyanova‐Beninska, Ingeborg Barišić, Giuseppe Capovilla, Armando Magrelli, Bruno Sepodes	5
5	Demonstrating significant benefit of orphan medicines: analysis of 15 years of experience in Europe 2017 ·Drug Discovery Today ·Laura Fregonese, (unknown), Matthias P. Hofer, Armando Magrelli, (unknown), Kristina Larsson, (unknown), Violeta Stoyanova‐Beninska, Stelios Tsigkos, Kerstin Westermark, Bruno Sepodes	15
6	Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditions 2017 ·Drug Discovery Today ·(unknown), Violeta Stoyanova‐Beninska, Giuseppe Capovilla, (unknown), Matthias P. Hofer, (unknown), Armando Magrelli, Segundo Mariz, Stelios Tsigkos, Evyenia Shaili, (unknown), Mario Ricciardi, (unknown), Pavel Balabanov, Kristina Larsson, Bruno Sepodes	11
7	Establishing rarity in the context of orphan medicinal product designation in the European Union 2017 ·Drug Discovery Today ·Stelios Tsigkos, Matthias P. Hofer, (unknown), Segundo Mariz, Kristina Larsson, (unknown), Laura Fregonese, Bruno Sepodes	7
8	Use of biomarkers in the context of orphan medicines designation in the European Union 2014 ·Orphanet Journal of Rare Diseases ·Stelios Tsigkos, (unknown), Segundo Mariz, (unknown), Laura Fregonese, Bożenna Dembowska–Bagińska, (unknown), Pauline Evers, (unknown), (unknown), (unknown), Daniel O’Connor, (unknown), Kerstin Westermark, Bruno Sepodes	6
9	Establishing medical plausibility in the context of orphan medicines designation in the European Union 2014 ·Orphanet Journal of Rare Diseases ·Stelios Tsigkos, Segundo Mariz, (unknown), Laura Fregonese, (unknown), (unknown), Kerstin Westermark, Bruno Sepodes	7
10	The orphan framework as a new opportunity: an expert opinion 2014 ·Expert Opinion on Orphan Drugs ·Segundo Mariz, Stelios Tsigkos, Laura Fregonese, (unknown), Eleonora Dehlink, (unknown), Bruno Sepodes	2
11	An Atypical Presentation of Visceral Leishmaniasis Infection in a Patient With Rheumatoid Arthritis Treated With Infliximab 2009 ·JCR Journal of Clinical Rheumatology ·K. Kritikos, (unknown), Stelios Tsigkos, (unknown), Ioanna Skrapari, (unknown), (unknown)	14
12	Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency 2009 ·European Journal of Clinical Pharmacology ·Jan Regnström, Franz Koenig, B. Aronsson, (unknown), Kristian Svendsen, Stelios Tsigkos, Bruno Flamion, Hans‐Georg Eichler, Spiros Vamvakas	83
13	Anti‐angiogenic properties of a sulindac analogue 2007 ·British Journal of Pharmacology ·Anastasia Pyriochou, Stelios Tsigkos, T. P. Vassilakopoulos, (unknown), Zongmin Zhou, Eleni Gourzoulidou, Charis Roussos, Herbert Waldmann, Athanassios Giannis, Andreas Papapetropoulos	20
14	Vascular endothelial growth factor–mediated induction of angiogenesis by human rhinoviruses 2006 ·Journal of Allergy and Clinical Immunology ·Stelios Psarras, (unknown), Chrysanthi Skevaki, Maria Xatzipsalti, Apostolos Bossios, Harris Pratsinis, Stelios Tsigkos, Dimitrios Gourgiotis, Andreas Constantopoulos, Andreas Papapetropoulos, Photini Saxoni‐Papageorgiou, Nikolaos G. Papadopoulos	71
15	Regulation of Ang2 release by PTEN/PI3‐kinase/Akt in lung microvascular endothelial cells 2006 ·Journal of Cellular Physiology ·Stelios Tsigkos, Zongmin Zhou, Αναστασία Κοτανίδου, David Fulton, Spyros Zakynthinos, Charis Roussos, Andreas Papapetropoulos	25
16	Angiopoietin-2 is increased in severe sepsis: Correlation with inflammatory mediators 2006 ·Critical Care Medicine ·Stylianos E. Orfanos, Αναστασία Κοτανίδου, Constantinos Glynos, (unknown), Stelios Tsigkos, Ioanna Dimopoulou, Christina Sotiropoulou, Spyros Zakynthinos, Apostolos Armaganidis, Andreas Papapetropoulos, Charis Roussos	180
17	Angiopoietin-2 Causes Inflammation in Vivo by Promoting Vascular Leakage 2005 ·Journal of Pharmacology and Experimental Therapeutics ·Fiorentina Roviezzo, Stelios Tsigkos, Αναστασία Κοτανίδου, Mariarosaria Bucci, Vincenzo Brancaleone, Giuseppe Cirino, Andreas Papapetropoulos	192
18	Angiopoietins in angiogenesis and beyond 2003 ·Expert Opinion on Investigational Drugs ·Stelios Tsigkos, (unknown), Andreas Papapetropoulos	100
19	Angiopoietins in angiogenesis and beyond 2003 ·Expert Opinion on Investigational Drugs ·Stelios Tsigkos, (unknown), Andreas Papapetropoulos	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact